Results 31 to 40 of about 381 (103)

In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination [PDF]

Antimicrobial Agents and Chemotherapy, 2020
Manogepix (APX001A) is the active moiety of the drug candidate fosmanogepix (APX001), currently in clinical development for the treatment of invasive fungal infections. We compared manogepix EUCAST minimum effective concentrations (MECs) to MICs of five comparators and CLSI MECs and MICs by a colorimetric method against contemporary molds.
Karin Meinike Jørgensen, Karen M. T. Astvad, Maiken Cavling Arendrup   +2 more
openaire   +6 more sources

Acute Lymphoblastic Leukemia and Invasive Mold Infections: A Challenging Field

Journal of Fungi, 2022
Acute lymphoblastic leukemia (ALL) patients comprise a highly immunocompromised group due to factors associated either with the treatment or the disease itself.
Christos Stafylidis, Panagiotis Diamantopoulos, Eleni Athanasoula, Elena Solomou, Amalia Anastasopoulou   +4 more
doaj   +1 more source

Manogepix, the Active Moiety of the Investigational Agent Fosmanogepix, Demonstrates In Vitro Activity against Members of the Fusarium oxysporum and Fusarium solani Species Complexes [PDF]

Antimicrobial Agents and Chemotherapy, 2021
We evaluated the in vitro activity of manogepix against Fusarium oxysporum and Fusarium solani species complex (FOSC and FSSC, respectively) isolates per CLSI document M38 broth microdilution methods.
Hamid Badali, Hoja P. Patterson, Carmita J. Sanders, Barbara Mermella, Connie F. C. Gibas, Ashraf S. Ibrahim, Karen J. Shaw, Nathan P. Wiederhold   +7 more
openaire   +2 more sources

Heightened Efficacy of Anidulafungin When Used in Combination with Manogepix or 5-Flucytosine against Candida auris In Vitro

Antimicrobial Agents and Chemotherapy, 2022
Candida auris is an emerging, multidrug-resistant fungal pathogen that causes refractory colonization and life-threatening, invasive nosocomial infections. The high proportion of C. auris isolates that display antifungal resistance severely limits treatment options.
Larissa L.H. John, Darren D. Thomson, Tihana Bicanic, Martin Hoenigl, Alistair J.P. Brown, Thomas S. Harrison, Elaine Bignell   +6 more
openaire   +3 more sources

In vitro manogepix susceptibility testing of South African Emergomyces africanus, Emergomyces pasteurianus, and Blastomyces emzantsi clinical isolates. [PDF]

Antimicrob Agents Chemother, 2023
ABSTRACT We performed in vitro antifungal susceptibility testing of manogepix against the yeast phase of 78 Emergomyces africanus , 2 Emergomyces pasteurianus, and 5 Blastomyces emzantsi isolates using a reference broth microdilution ...
Nzimande SP, Govender NP, Maphanga TG.
europepmc   +3 more sources

Manogepix (APX001A) In Vitro Activity against Candida auris: Head-to-Head Comparison of EUCAST and CLSI MICs

Antimicrobial Agents and Chemotherapy, 2020
Fosmanogepix is a novel prodrug in a new class of antifungal agents. Manogepix is the active moiety. We evaluated the CLSI and EUCAST MICs of manogepix and eight comparators against Candida auris . CLSI M27-A3 susceptibility testing of manogepix was performed for 122 C.
Maiken Cavling Arendrup, Anuradha Chowdhary, Karin Meinike Jørgensen, Joseph Meletiadis   +3 more
openaire   +5 more sources

1275. Evaluation of in vitro activity of manogepix against multidrug-resistant and pan-resistant Candida auris from the New York Outbreak [PDF]

Open Forum Infectious Diseases, 2020
Abstract Background An ongoing Candida auris outbreak in the New York metropolitan area is the largest recorded to date in North America. NY C. auris isolates demonstrate resistance to fluconazole and variable resistance to other antifungals.
Zhu, Yan Chun, Kilburn, Shannon N, Kapoor, Mili, Chaturvedi, Sudha, Shaw, Karen J, Chaturvedi, Vishnu   +5 more
openaire   +1 more source

Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in <i>Candida auris</i> (<i>Candidozyma auris</i>), <i>Candida albicans</i>, <i>Candida parapsilosis</i>, and <i>Candida glabrata</i> (<i>Nakaseomyces glabratus</i>). [PDF]

Antimicrob Agents Chemother
ABSTRACT The fungal pathogen Candida auris is of global concern due to high levels of multidrug resistance and its propensity to cause infectious outbreaks.
Barker KS, Patterson HP, Morschhäuser J, Cuomo CA, Wiederhold NP, Rogers PD.   +5 more
europepmc   +3 more sources

1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type [PDF]

Open Forum Infectious Diseases, 2020
Abstract Background Existing antifungal agents are active against many common fungal pathogens; however, breakthrough fungal infections occur and often involve less frequently encountered yeast and mould isolates.
Huband, Michael D, Pfaller, Michael A, Flamm, Robert K, Messer, Shawn A, Schaefer, Beth A, Bien, Paul, Castanheira, Mariana   +6 more
openaire   +1 more source

Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs

Antimicrobial Agents and Chemotherapy, 2020
Manogepix (APX001A) is the active moiety of the novel drug candidate fosmanogepix (APX001). We previously reported the broad-spectrum activity of manogepix but also observed a correlation between increased manogepix and fluconazole MICs. Here, we extended this study and included isolates with acquired fluconazole resistance. Isolates (
Maiken Cavling Arendrup, Karin Meinike Jørgensen   +1 more
openaire   +4 more sources